University of Pennsylvania Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

MET Exon 14 Skipping Mutations and Crizotinib
Joshua Bauml, MD of the University of Pennsylvania discusses MET Exon 14 Skipping Mutations and Crizotinib from the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imedex.com/perspect'>http://imedex.com/perspect...</a>... Author: thoraciconcology Added: 12/28/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 28, 2017 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy in Lung Cancer Unselected Patients Response Rate 15-20 Percent
Joshua Bauml, MD of the University of Pennsylvania discusses immunotherapy in lung cancer unselected patients response rate is only 15-20 percent at the 22nd Annual Perspectives in Thoracic Oncology i... Author: thoraciconcology Added: 12/28/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 28, 2017 Category: Cancer & Oncology Source Type: podcasts

HER2 Over Expressed in 60 percent of NSCLC
Joshua Bauml, MD of the University of Pennsylvania discusses the fact that HER2 is over expressed in 60 percent of NSCLC from the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imede'>http://imede...</a>... Author: thoraciconcology Added: 12/28/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 28, 2017 Category: Cancer & Oncology Source Type: podcasts

T790M Testing Practically Standard for EGFR Activating Patients
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how T790M testing is practically standard for EGFR activating patients from the 22nd Annual Perspectives in Thoracic Oncology in N... Author: thoraciconcology Added: 12/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 27, 2017 Category: Cancer & Oncology Source Type: podcasts

Pacific Trial Durvalumab in Locally Advanced NSCLC Strikingly Positive Data
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses the Pacific Trial overview of Durvalumab in Locally Advanced NSCLC and how it presented strikingly positive data from the 22nd Ann... Author: thoraciconcology Added: 12/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 27, 2017 Category: Cancer & Oncology Source Type: podcasts

PACIFIC Trial Concerns Survival Data Not Released - PFS May Not Be Enough
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses his concerns over the PACIFIC Trial data such as the survival data not being released and how significant PFS may not be enough fr... Author: thoraciconcology Added: 12/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 27, 2017 Category: Cancer & Oncology Source Type: podcasts

FLAURA Trial Results 8-9 Month PFS in Treatment Naive EGFR
Corey J. Langer, MD, FACP of the University of Pennsylvania talks about the FLAURA Trial Results and the 8-9 Month PFS in Treatment Naive EGFR patients from the 22nd Annual Perspectives in Thoracic On... Author: thoraciconcology Added: 12/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 27, 2017 Category: Cancer & Oncology Source Type: podcasts

In EGFR Activating Mutations Osimertinib is Now The Standard of Care
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how in EGFR Activating Mutations Osimertinib is Now The Standard of Care from the 22nd Annual Perspectives in Thoracic Oncology in... Author: thoraciconcology Added: 12/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 27, 2017 Category: Cancer & Oncology Source Type: podcasts

2018 NSCLC Trends in Prognosticate Refinement and the " Tsunami " of Trials Assessing Combinations of Drugs
Corey J. Langer, MD, FACP of the University of Pennsylvania talks about 2018 NSCLC Trends in Prognosticate Refinement and the "Tsunami" of Trials Assessing Combinations of Drugs from the 22nd Annual P... Author: thoraciconcology Added: 12/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 27, 2017 Category: Cancer & Oncology Source Type: podcasts

What Determines using Osimertinib in First Line Treatment
Tracey L. Evans, MD of the University of Pennsylvania describes What Determines using Osimertinib in First Line Treatment from the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imed'>http://imed...</a>... Author: thoraciconcology Added: 12/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 26, 2017 Category: Cancer & Oncology Source Type: podcasts

T790 Mutation Testing on Initial Diagnosis
Tracey L. Evans, MD of the University of Pennsylvania discusses T790 Mutation Testing on Initial Diagnosis from the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imedex.com/perspect'>http://imedex.com/perspect...</a>... Author: thoraciconcology Added: 12/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 26, 2017 Category: Cancer & Oncology Source Type: podcasts

Incomplete Resections in NSCLC
Tracey L. Evans, MD of the University of Pennsylvania discusses Incomplete Resections in NSCLC from the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imedex.com/perspectives-thoraci'>http://imedex.com/perspecti...</a>... Author: thoraciconcology Added: 12/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 26, 2017 Category: Cancer & Oncology Source Type: podcasts

Impact of Immunotherapy in Thoracic Oncology
Tracey L. Evans, MD of the University of Pennsylvania discusses the Impact of Immunotherapy in Thoracic Oncology at the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imedex.com/pers'>http://imedex.com/pers...</a>... Author: thoraciconcology Added: 12/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 26, 2017 Category: Cancer & Oncology Source Type: podcasts

Why is Breakthrough of Osimertinib in EGFR Mutated NSCLC
Tracey L. Evans, MD of the University of Pennsylvania describes why Osimertinib is such a breakthrough in EGFR Mutated NSCLC at the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://ime'>http://ime...</a>... Author: thoraciconcology Added: 12/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 26, 2017 Category: Cancer & Oncology Source Type: podcasts

Why is Breakthrough of Osimertinib in EGFR Mutated NSCLC Important
Tracey L. Evans, MD of the University of Pennsylvania describes why Osimertinib is such an important breakthrough in EGFR Mutated NSCLC at the 22nd Annual Perspectives in Thoracic Oncology in New York... Author: thoraciconcology Added: 12/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 26, 2017 Category: Cancer & Oncology Source Type: podcasts